These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CD47 expression and CD163 Imam R; Chang Q; Black M; Yu C; Cao W BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961 [TBL] [Abstract][Full Text] [Related]
4. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297 [TBL] [Abstract][Full Text] [Related]
5. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. Shi J; Lu P; Shen W; He R; Yang MW; Fang Y; Sun YW; Niu N; Xue J Cancer Lett; 2019 Jul; 453():158-169. PubMed ID: 30954649 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma. Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056 [TBL] [Abstract][Full Text] [Related]
7. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies. Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099 [TBL] [Abstract][Full Text] [Related]
9. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112 [TBL] [Abstract][Full Text] [Related]
10. Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. Liu M; O'Connor RS; Trefely S; Graham K; Snyder NW; Beatty GL Nat Immunol; 2019 Jan; 20(3):265-275. PubMed ID: 30664738 [TBL] [Abstract][Full Text] [Related]
11. Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors. Nilubol N; Yuan Z; Paciotti GF; Tamarkin L; Sanchez C; Gaskins K; Freedman EM; Cao S; Zhao J; Kingston DGI; Libutti SK; Kebebew E J Natl Cancer Inst; 2018 Sep; 110(9):1019-1029. PubMed ID: 29481652 [TBL] [Abstract][Full Text] [Related]
12. Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors. Hunter KE; Palermo C; Kester JC; Simpson K; Li JP; Tang LH; Klimstra DS; Vlodavsky I; Joyce JA Oncogene; 2014 Apr; 33(14):1799-808. PubMed ID: 23644656 [TBL] [Abstract][Full Text] [Related]
13. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Baccelli I; Stenzinger A; Vogel V; Pfitzner BM; Klein C; Wallwiener M; Scharpff M; Saini M; Holland-Letz T; Sinn HP; Schneeweiss A; Denkert C; Weichert W; Trumpp A Oncotarget; 2014 Sep; 5(18):8147-60. PubMed ID: 25230070 [TBL] [Abstract][Full Text] [Related]
14. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on. Mohanty S; Aghighi M; Yerneni K; Theruvath JL; Daldrup-Link HE Mol Oncol; 2019 Oct; 13(10):2049-2061. PubMed ID: 31376208 [TBL] [Abstract][Full Text] [Related]
15. Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Pea A; Hruban RH; Wood LD Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978 [TBL] [Abstract][Full Text] [Related]
16. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Matlung HL; Szilagyi K; Barclay NA; van den Berg TK Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703 [TBL] [Abstract][Full Text] [Related]
17. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors. Tzatzarakis E; Hissa B; Reissfelder C; Schölch S Expert Rev Anticancer Ther; 2019 Nov; 19(11):993-999. PubMed ID: 31686549 [No Abstract] [Full Text] [Related]
18. p53 and p16 Azzopardi S; Pang S; Klimstra DS; Du YN Neoplasia; 2016 Oct; 18(10):610-617. PubMed ID: 27664376 [TBL] [Abstract][Full Text] [Related]
19. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Yoshida K; Tsujimoto H; Matsumura K; Kinoshita M; Takahata R; Matsumoto Y; Hiraki S; Ono S; Seki S; Yamamoto J; Hase K Cancer Med; 2015 Sep; 4(9):1322-33. PubMed ID: 26077800 [TBL] [Abstract][Full Text] [Related]
20. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Jiang J; Zhang Y; Chuai S; Wang Z; Zheng D; Xu F; Zhang Y; Li C; Liang Y; Chen Z Oncogene; 2012 Feb; 31(6):671-82. PubMed ID: 21743497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]